Preclinical tests show promise against primary effusion lymphoma

06/27/2013 | InfectionControlToday.com

A study in the journal Oncogene found that a class of drugs called BET bromodomain inhibitors can effectively treat primary effusion lymphoma, a rare and aggressive blood cancer. The disease is caused by infection with Kaposi's sarcoma-associated herpes virus and is most commonly seen among patients with HIV. Inhibitors targeting the BRD4 protein halted the growth of PEL cells in laboratory and animal tests.

View Full Article in:

InfectionControlToday.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations